Oct 03, 2022 / 12:50PM GMT
Jason Matthew Gerberry - BofA Securities, Research Division - MD in US Equity Research
Hello, everybody. My name is Jason Gerberry, I'm one of the biotech analysts at BofA, and I'm pleased to kicking off BofA's first Precision Oncology Day Event. And we've assembled here for a collection of companies doing some of the more relevant clinical research in the field of precision oncology, and we've assembled a couple of expert panels to discuss relevant sector topics. So hopefully, you can join our lung cancer panel as well as our VC panel. And just to start things off, I just wanted to thank all of our participants in today's event for contributing. And I think what should be a pretty fruitful set of discussions.
And before we head it off to our first company fireside, I just wanted to say a few words as to why we view precision oncology as an interesting area from an investor perspective. First, despite a difficult market backdrop, particularly for biotech companies, we see the field of precision oncology is interesting given we have an accommodative regulatory backdrop, a number of targets that
HUTCHMED (China) Ltd at Bank of America Precision Oncology Conference Transcript
Oct 03, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers